Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products and could be used to respond to an emerging pandemic ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs such ...

Sanofi, MSD, Novartis, and Roche among AbbVie’s neighbours. “We are grateful for AbbVie’s continued trust in the strength of Singapore’s biopharmaceutical manufacturing capabilities and ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners reiterated a Buy rating on the ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to €123.00. Graham Parry has given his Buy rating due ...